131 related articles for article (PubMed ID: 38804019)
1. Effectiveness and safety of mogamulizumab for the treatment of Sézary syndrome in very elderly patients: A real-world, multicentre, retrospective study conducted in France.
Ribereau-Gayon E; Beylot-Barry M; De Masson A; Ram-Wolff C; Bagot M; Pham-Ledard A; Grange F
J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38804019
[No Abstract] [Full Text] [Related]
2. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
[TBL] [Abstract][Full Text] [Related]
3. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
Algarni AS; Ram-Wolff C; Bagot M; De Masson A
Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
Muszbek N; Remak E; Xin Q; McNamara L; Jones T
J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
[No Abstract] [Full Text] [Related]
6. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
[No Abstract] [Full Text] [Related]
7. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
9. Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study.
Jouandet M; Nakouri I; Nadin L; Kieny A; Samimi M; Adamski H; Quéreux G; Chaby G; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406431
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
11. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
12. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas.
Caruso L; Castellino A; Dessì D; Flenghi L; Giordano A; Ibatici A; Massone C; Pileri A; Proietti I; Pupo L; Quaglino P; Rupoli S; Zinzani PL
Cancer Manag Res; 2022; 14():3205-3221. PubMed ID: 36444356
[TBL] [Abstract][Full Text] [Related]
13. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
14. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
[TBL] [Abstract][Full Text] [Related]
15. An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
L'Orphelin JM
Ther Adv Hematol; 2024; 15():20406207241235777. PubMed ID: 38456078
[TBL] [Abstract][Full Text] [Related]
16. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
Watson S; Marx JB
J Adv Pract Oncol; 2019; 10(8):883-888. PubMed ID: 33425472
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.
Virgen CA; Sparks JA; Nohria A; O'Hare MJ; Goyal A; Said JT; Tawa M; LeBoeuf NR; Kupper TS; Fisher DC; Larocca C
Oncologist; 2023 Aug; 28(8):e694-e698. PubMed ID: 37285523
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
[No Abstract] [Full Text] [Related]
20. Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient.
Lolli G; Casadei B; Argnani L; Nanni L; Cavo M; Zinzani PL
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020040. PubMed ID: 32670518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
